PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) “Gets It Right” in Cannabinoid Extraction
- Sol-gel nose-to-brain system offers superior drug delivery
- New extraction protocol makes accurate and precise quantification of cannabinoids possible
- Establishment of cannabis division to commercialize research developments
A recent release from PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) shows that, in cannabinoid extraction technology, the health sciences company is getting it right. The company announced that, during its soluble gel drug delivery research and development program – the Sol-gel Program – it had successfully optimized the conditions for extracting cannabinoids from one of its cannabis strains and developed a proprietary method – the Extraction Protocol – for the accurate and precise quantification of cannabinoids present in the extract (http://nnw.fm/wC7bs). This technological triumph will allow PRVCF to generate a range of cannabinoid-based Sol-gel formulations, each with a distinct, well-defined composition profile, based on specifications from clinical trial data that determine efficacy and safety. PRVCF is expecting that its drug delivery Sol-gel system will be employed in a range of therapeutic applications that target, initially, anxiety, cachexia, chemotherapy-induced nausea and pain.
The accuracy and precision of PreveCeutical’s Extraction Protocol has been checked against eight commercial cannabinoid standards over a broad concentration range. Its validation means that it can now be directly applied to the four other cannabis strains used in the Sol-gel program. The Extraction Protocol will expedite the creation of a library of chemically fingerprinted cannabinoid extracts, each with a complementary cannabinoid composition. These unique extracts will be optimized and integrated with the Sol-gel technology for use in a variety of therapeutic applications.
To complement the sophistication of its extraction and formulation methodologies, PreveCeutical is in search of hardware for its cannabinoid Sol-gel technology. As Dr. Harry Parekh explained in a recent interview, CBD Sol-gel is a nose-to-brain delivery system and so optimizing the “spray profile” is just as important as getting the formulation right (http://nnw.fm/pP8Su). Formulation and spray profiles go “hand in hand.” PRVCF has been working very closely with the global leader in spray device manufacture, a company based in Europe, in a quest for the optimal applicator. PreveCeutical has now narrowed its choice to two devices that appear to be “optimal for the delivery of the cannabinoid sol-gels into the nasal cavity.”
Most nasal application methods require “upwards of one or two dozen sprays, every twenty-hour hours, which is effectively the patient drinking it, post-nasally.” However, PRVCF believes that its approach will have the edge, because its spray will gel as soon as it hits the nasal mucosa, avoiding any post-nasal swallowing, and, therefore, one-to-three applications per week may be all that is required.
The Sol-gel system is an innovative nose-to-brain drug delivery platform that holds the promise of making medication regimens more effective. When therapeutic compounds are taken orally (many are), they travel through the stomach and intestines and are metabolized, which reduces their effectiveness. However, the Sol-gel system works by nasal administration and delivers the therapeutic agent to the mucosal tissue lining the nostrils, where it is transmitted rapidly to the brain, increasing bioavailability. Additionally, the gel stays in the nasal passages, slowly releasing the CBD while keeping it active for up to seven days. This ease of application and its long-lasting effects may be attractive for patients when compared to other delivery systems.
PreveCeutical has established a cannabis division to commercialize its advances with the cannabinoid Sol-gel technology (http://nnw.fm/O27cf).
“Given the progress we have made with the extractions and the refined formulations… we believe they can now be channeled into multiple different dosage forms – wafers, tablets, or sprays – so there’s a whole range of different applications that we can put the base technology into for a range of different clinical applications,” Parekh stated in a news release.
For the millions who suffer from anxiety, cachexia, chemotherapy-induced nausea and pain, this is good news. Clinical trials are expected to begin by the end of 2019.
For more information, visit the company’s website at www.PreveCeutical.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer